The FDA alignment on a single registrational trial and strong Phase 2a efficacy/tolerability data significantly de-risk AlloNK's path to market. Traders should watch for the official FDA minutes and initiation of the Phase 3 trial in H2 2026 as key catalysts. The stock may re-rate upward given the large refractory RA market opportunity and the off-the-shelf advantage over CAR-T.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $10.89entry
- T+1 · 6mo ago −2.66%α −2.89% · $10.60
- T+5 · 6mo ago −1.93%α −3.39% · $10.68
- T+20 · 5mo ago −37.10%α −37.12% · $6.85
- T+60 · 3mo ago +1.65%α −3.19% · $11.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six months in its company-sponsored trial, and FDA alignment on a single registrational Phase 3 trial expected to start H2 2026. The data supports AlloNK's potential as an off-the-shelf deep B-cell depleting therapy with a favorable outpatient tolerability profile, de-risking the path to a BLA submission in 2029.
Key Facts
- 71% ACR50 response at six months in company-sponsored Phase 2a basket trial (5 of 7 patients) in refractory RA.
- FDA alignment on a single registrational Phase 3 trial for AlloNK in refractory RA, with ACR50 at six months as primary endpoint.
- Phase 3 trial expected to enroll ~150 patients, randomized 2:1 AlloNK+rituximab vs rituximab alone, with crossover option.
- No CRS, ICANS, or treatment discontinuations observed in autoimmune patients; tolerability supports outpatient community administration.
- More than 70 autoimmune patients treated with AlloNK across >40 active clinical sites, mostly in community settings.
- B-cell depletion observed uniformly by Day 13 in all 51 evaluable patients; B-cell reconstitution shows naïve/transitional predominance consistent with 'reset'.
- Initial data in Sjögren disease (n=7 at 6 months) and systemic sclerosis (n=4 at 6 months) show consistent clinical improvements.
- Artiva expects to initiate Phase 3 in H2 2026, report primary efficacy data in H2 2028, and submit BLA in 2029.
- Artiva estimates 150,000-200,000 refractory RA patients in the U.S. who have failed ≥2 b/tsDMARDs, with only 11-19% ACR50 likelihood on current therapies.
Financial Impact
No financial data provided in press release; market cap ~$309M. Positive clinical data and FDA alignment likely to increase valuation if Phase 3 succeeds.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint or show safety issues in a larger population.
- FDA minutes from recent interaction could include requests for additional data or different trial design.
- Competition from other deep B-cell depleting therapies (e.g., CAR-T, bispecifics) could limit market share.
- Artiva will need additional financing to complete Phase 3 and BLA submission; dilution risk exists.
- Pooled data from separate trials (company-sponsored and IIT) may not be directly comparable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290957 |
Track record
33 reports on ARTV
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers